Loading...
Ayurcann Holdings Corp.
AYUR.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.03
CA$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $5.81M in Q2 2023 to $8.31M in Q1 2024. Gross profit remained healthy with margins at 38% in Q1 2024 compared to 33% in Q2 2023. Operating income hit -$139452.00 last quarter, sustaining a consistent -2% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $86211.00. Net income rose to -$356711.00, while earnings per share reached -$0.002. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan